Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-cash Items: 2017-2024

  • UroGen Pharma's Non-cash Items fell 60.01% to $2.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.1 million, marking a year-over-year decrease of 60.01%. This contributed to the annual value of $1.1 million for FY2024, which is 78.72% down from last year.
  • Per UroGen Pharma's latest filing, its Non-cash Items stood at $2.1 million for Q4 2024, which was down 60.01% from $5.1 million recorded in Q4 2023.
  • UroGen Pharma's Non-cash Items' 5-year high stood at $13.5 million during Q4 2020, with a 5-year trough of $1.9 million in Q4 2022.
  • Over the past 3 years, UroGen Pharma's median Non-cash Items value was $2.1 million (recorded in 2024), while the average stood at $3.0 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first plummeted by 84.08% in 2021, then soared by 168.63% in 2023.
  • Over the past 5 years, UroGen Pharma's Non-cash Items (Quarterly) stood at $13.5 million in 2020, then crashed by 84.08% to $2.1 million in 2021, then dropped by 11.15% to $1.9 million in 2022, then surged by 168.63% to $5.1 million in 2023, then slumped by 60.01% to $2.1 million in 2024.
  • Its last three reported values are $2.1 million in Q4 2024, $5.1 million for Q4 2023, and $1.9 million during Q4 2022.